Evaluation of Geistlich Fibro-Gide ® and Autogenous Connective Tissue Graft Prior to Orthodontic Maxillary Expansion.
Launched by UNIVERSITY OF ALBERTA · Mar 15, 2022
Trial Information
Current as of June 15, 2025
Withdrawn
Keywords
ClinConnect Summary
This study will be a prospective, single-center, blinded, randomized, split-mouth study. Upon ethics approval from the University of Alberta research information services (ARISE), patients will be recruited from Kaye Edmonton Clinic (KEC). This study evaluates the long-term success of Geistlich Fibro-Gide® in comparison to autogenous connective tissue graft for the treatment of gingival phenotype modification of patients with thin gingiva undergoing orthodontic arch expansion in the KEC Graduate Orthodontics clinic. A total of 30 subjects (n=30) will be enrolled in this study. Sample size w...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Inclusion criteria for this study include patients ranging from 13 to 17 years of age requiring maxillary expansion;
- • presence of all permanent dentition, presence of unilateral or bilateral cross-bite or transverse maxillary deficiency,
- • subjects must have at least one tooth with thin gingival phenotype on maxillary canines, premolars or first molars (mesial root only) on either side;
- • teeth should have less than 2 mm of keratinized gingiva to be considered for surgical intervention
- • subjects should be systemically health.
- Exclusion Criteria:
- • Exclusion criteria would include patients with previous orthodontic treatment done,
- • patients with Class V restorations or abfractions that obliterate cementoenamel junction
- • patients with active caries or endodontically involved teeth
- • immunocompromised patients that can influence wound healing
- • patients with parafunctional habits
- • patient with any history of smoking
- • pregnant or lactating females
- • teeth that have greater than Miller grade I mobility.
About University Of Alberta
The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Patients applied
Trial Officials
Monica P Gibson, BDS,MS(Perio),PhD,FRCD(C)
Principal Investigator
U of Alberta Co-Director,Perio Graduate Prog,Faculty of Medicine & Dentistry-Dentistry Dept
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials